New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
12:25 EDTBIIB, BIIB, BAX, BAX, ALNY, ALNY, NKTR, NKTR, SGMO, SGMO, SHPG, SHPG, CSL, CSL, PFE, PFE, NVO, NVOPiper Jaffray's healthcare analysts hold an analyst/industry conference call
Analysts, along with Dr. Powell, Director of the Hemophilia Treatment Center at UC Davis Health System, review the current treatment paradigm for Hemophilia A and Hemophilia B on an Analyst/Industry conference call to be held on March 7 at 1 pm.
News For BIIB;BAX;ALNY;NKTR;SGMO;SHPG;CSL;PFE;NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 20, 2014
12:23 EDTSHPGAllergan holder Paulson encourages deal with Shire, Reuters says
Subscribe for More Information
12:21 EDTSHPGCooperman says bought Shire as 'small position'
Subscribe for More Information
11:12 EDTNKTRNektar management to meet with Roth Capital
Subscribe for More Information
09:22 EDTSHPGOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTBAXBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
07:47 EDTSHPG, PFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:33 EDTSHPGShire upgraded to Buy from Neutral at SunTrust
Subscribe for More Information
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
07:19 EDTSHPGIBC Life Sciences to hold a conference
Subscribe for More Information
07:16 EDTSHPGAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:15 EDTPFE, SHPGAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFE, SHPGAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
06:56 EDTSHPGShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
05:29 EDTSHPGShire Interim CFO James Bowling to step down
Shire plc announces that James Bowling, Interim CFO, has notified the board of his decision to step down from his current role to pursue a new career opportunity as CFO of Severn Trent plc. James will leave Shire at the end of 1Q15 and the company will commence a search for a new CFO immediately.
October 17, 2014
16:55 EDTSHPGStocks end volatile week lower amid oil price plunge
Subscribe for More Information
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
07:07 EDTSHPGShire may be buyer instead of target if AbbVie deal breaks, WSJ says
Assuming AbbVie's (ABBV) deal to buy Shire (SHPG) gets cancelled, which appears likely at this point, many analysts and investors believe Shire will become a buyer and Leerink Partners estimates the company could have $10B to use for a takeover deal, reported The Wall Street Journal. AbbVie will also be likely to look for other deals and could be forced to pay up for them, as its top seller, Humira, moves closer to losing patent exclusivity, the Journal said, citing analysts. Reference Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use